Laevolac (Lactulose, Liquid)

Lactulose is a synthetic sugar that reaches the colon unchanged, where intestinal bacteria break it down into short‑chain fatty acids. These acids increase the osmotic pressure in the colon, drawing water into the lumen, and they lower the colonic pH, converting ammonia to ammonium, which is trapped and eliminated, thereby reducing systemic ammonia.

The dose of Laevolac is individualized by the prescribing healthcare professional based on the patient’s age, weight, severity of constipation or hepatic encephalopathy, and response to therapy. No fixed regimen is provided here; the prescriber will set the appropriate dose and titration schedule.

Safety data for lactulose in pregnancy and lactation are limited. It is generally considered low risk because it is poorly absorbed, but clinicians should weigh potential benefits against any uncertain risks and discuss use with a qualified healthcare provider before starting treatment.

To request Laevolac, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lactulose and polyethylene glycol (PEG) act as osmotic agents, but lactulose also acidifies the colon and reduces ammonia absorption, making it useful for hepatic encephalopathy. PEG is inert and primarily used for constipation without the ammonia‑lowering effect. Choice depends on the clinical indication and patient tolerance.

Laevolac should be stored at ambient temperature, preferably below 25 °C. Keep the bottle tightly closed in its original packaging, protect it from moisture and direct sunlight, and discard any product that appears discolored or contains particles.

Laevolac is taken orally as a liquid solution. The prescribed volume is measured with a calibrated dosing device and ingested, usually once or twice daily, with or without food, according to the prescriber’s instructions.

Serious risks, although rare, include severe electrolyte disturbances such as hyponatremia or hypokalemia, marked dehydration from excessive diarrhea, and allergic reactions that may present as rash, urticaria or angioedema. Patients should seek medical attention promptly if any of these occur.

Laevolac should be avoided in patients with known hypersensitivity to lactulose, those with severe renal impairment where fluid balance is critical, and individuals with intestinal obstruction or perforation. Caution is also advised for patients with diabetes, as lactulose can affect blood glucose levels.